Immunotherapy and Targeted Therapy in Breast Cancer
Breast cancer remains a major cause of cancer mortality worldwide. The hope for improved survival of breast cancer patients comes from the many immunotherapeutic and targeted therapeutic strategies currently being studied. These strategies include the approved clinical use of immunotherapeutic checkpoint inhibitors for metastatic triple-negative breast cancer positive for PD-L1 expression and poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of BRCA-deficient breast cancers. Although promising, the responses to these targeted strategies are limited and additional advances in patient stratification and novel drug/target combinations are needed. We invite breast cancer studies that investigate the various aspects of immunotherapeutic and targeted therapeutic strategies. In this Topic, original research articles and reviews are welcome. Breast cancer research areas may include (but are not limited to) pre-clinical and clinical studies that investigate the various aspects of immunotherapeutic and targeted therapeutic strategies, as well novel methods of drug delivery.
Dr. Paola Marcato
Dr. Suresh Gadde
- breast cancer
- immune checkpoint blockade
- precision medicine
- cancer nanomedicine
|Journal Name||Impact Factor||CiteScore||Launched Year||First Decision (median)||APC|
|4.2||4.0||2012||18.8 Days||CHF 2700|
|5.2||7.4||2009||18.2 Days||CHF 2900|
|2.6||2.6||1994||18.4 Days||CHF 2200|
|3.7||-||2013||20.2 Days||CHF 1600|
|-||-||2021||15.0 days *||CHF 1000|
* Median value for all MDPI journals in the first half of 2023.
Preprints is a platform dedicated to making early versions of research outputs permanently available and citable. MDPI journals allow posting on preprint servers such as Preprints.org prior to publication. For more details about reprints, please visit https://www.preprints.org.